EMA Withdrawn: Zoledronic acid Teva Pharma (zoledronic acid) — Teva B.V.

View source ↗

Summary

EMA withdrew zoledronic acid Teva Pharma (zoledronic acid) from the market in 2018 for indications including osteoporosis, osteitis deformans, and postmenopausa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteitis Deformans
• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Zoledronic acid Teva Pharma (zoledronic acid)

Snippet

Status: Withdrawn. Therapeutic area: Osteoporosis;Osteitis Deformans;Osteoporosis, Postmenopausal. MAH: Teva B.V.. Decision date: 18/01/2018